IonQ’s 755% Revenue Surge and $13M Institutional Bet Buck Quantum Rotation

IonQ shares dip 4% amid rotation to IBM, but record Q1 revenue, $13M institutional buy, and SkyWater acquisition signal strong fundamentals.

IonQ’s stock slipped about 4% to near $69 in early June, a rare pullback for a name that had surged 71% the previous month. The culprit? A rotation into IBM, which jumped 7% on the first trading day of the month as institutional investors traded the pure-play quantum stock for the safer, dividend-paying blue chip. Yet beneath the surface, a very different story is playing out—one of record revenues, deep-pocketed institutional accumulation, and a $13 million vote of confidence from a European asset manager.

The rotation from speculative quantum names into IBM—which also benefits from a lower beta and decades of corporate client relationships—hit IonQ and its peers hard. Rigetti Computing and D-Wave each fell similarly after their own triple-digit percentage runs in May. Analysts see the move as classic profit-taking after an extraordinary rally, not a fundamental shift in the company’s trajectory.

Indeed, IonQ just posted its strongest quarter ever. First-quarter 2026 revenue hit $64.67 million, a 755% year-over-year surge that landed 30% above the company’s own guidance. Helped by strong system sales and rising demand for its Tempo architecture, IonQ raised its full-year revenue outlook to between $260 million and $270 million.

The growth is attracting heavyweight institutional investors. Italian asset manager Eurizon Capital SGR opened a new position worth roughly $13 million, while Intech Investment Management expanded its stake by 36.2%, now holding shares valued at $4.8 million. Combined, institutional investors now own 41.42% of IonQ’s outstanding shares—a level that suggests conviction runs deep, even as the stock trades above the consensus analyst target of $67.64.

IonQ’s financial position lends further credence to the bull case. The company carries no debt and holds $3.1 billion in cash and investments—enough to fund operations for years. That is fortunate because the business remains deeply unprofitable on an adjusted EBITDA basis, which came in at a loss of $96.8 million for the quarter. Yet the backlog of contracted future revenue, measured as remaining performance obligations, swelled over 550% to roughly $470 million, signaling strong long-term customer commitment.

A major strategic pivot is the planned $1.8 billion acquisition of SkyWater Technology. IonQ will pay $35.00 per share in a cash-and-stock deal that has already won unanimous approval from both boards and SkyWater shareholders. The goal is to create the only vertically integrated quantum computing platform with its own US manufacturing site. The deal is expected to close in the second or third quarter of 2026, pending regulatory clearance.

Short sellers remain a wild card. Although short positions were cut by 12.47% recently, 20.71% of the float is still sold short—a level that amplifies both downside risk on bad news and squeeze potential on positive catalysts. The current price-to-sales multiple of roughly 120x leaves little room for error, as even bullish analysts acknowledge the stock has run ahead of its valuation framework.

Several near-term events could tip the scales. On June 9, management presents at the Mizuho Global Technology Conference, followed by the Rosenblatt Annual Technology Summit the next day. More consequential is the annual general meeting on June 16, where executives are expected to detail the company’s government contract pipeline and sovereign quantum strategy. Meanwhile, IBM CEO Arvind Krishna’s prediction that the industry will deliver the first demonstrable “quantum advantage” within the year—solving a commercially relevant problem faster than any classical computer—could provide a sector-wide lift. IonQ recently demonstrated the photonic connection of two ion-trap systems, a technical prerequisite for scalable, fault-tolerant architectures. If that milestone translates into customer wins, the rotation out of pure plays may prove short-lived.